KIOS-I: Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder

Sponsor
Biomedical Development Corporation (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05859035
Collaborator
The University of Texas Health Science Center at San Antonio (Other), National Institute on Drug Abuse (NIDA) (NIH)
25
1
1

Study Details

Study Description

Brief Summary

This study will evaluate the feasibility of an app that provides drug information to people in recovery from opioid use disorder. This study is designed to test the prototype app, not to determine health outcomes. The study will confirm the design and operating specifications prior to being evaluated in a larger clinical trial.

Condition or Disease Intervention/Treatment Phase
  • Device: KIOS Informational App
N/A

Detailed Description

The overall study is designed in two steps: 1) a one-week proof-of-concept study; and 2) a one-month pilot study.

Step 1: A one-week proof-of-concept study will be performed in a small population (n=5) of individuals in opioid use disorder recovery as an indicator of the app's suitability. Study participants will use the sham app for one week and will then complete a usability and user satisfaction survey. If the app is found to be exhibit acceptable usability and satisfaction, a one month study will be completed in a larger sample (see Step 2, below). If not, modifications to the app will be made and the one-week study will be repeated in a new group of participants.

Step 2: After completion of the proof-of-concept study, 20 new participants will be enrolled in a 4-week trial. Study participants will complete baseline assessments and then be asked to use the app at least three times per week, for four weeks. At the end of four weeks, participants will complete usability and user satisfaction surveys.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: KIOS Informational App evaluation

Study participants will use the app at least three times per week. The app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing "Thank You" screen.

Device: KIOS Informational App
The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing "Thank You" screen.
Other Names:
  • KIOS-I
  • Outcome Measures

    Primary Outcome Measures

    1. Usability Score [The Systems Usability Scale will be administered at the end of one-week for participants enrolled in Step 1 of the study and at the end of four-weeks for participants enrolled in Step 2.]

      The Systems Usability Scale-Modified is a non-health outcome, single-factor, 10-item self-report scale commonly used to evaluate participants' subjective experience using software. Systems Usability Scale yields a single number representing a composite measure of the overall usability of the system being studied. Systems Usability Scale scores have a range of 0 to 100, with higher scores representing a better outcome. Systems in early development may expect to have a rating of 30, while more mature systems should rate between 60 - 80.

    Secondary Outcome Measures

    1. User Satisfaction [A user satisfaction survey will be administered at the end of one-week for participants enrolled in Step 1 of the study and at the end of four-weeks for participants enrolled in Step 2.]

      A user satisfaction survey will be administered to evaluate the study participants' overall satisfaction with the app. This is a non-health outcome designed to better understand the user's perception of the app. The survey will consist of 20 statements that users will rate on a 1-7 Likert type scale (1=Disagree, 7= Agree). Satisfaction scores will be averaged and converted to percentages with higher percentages representing better user satisfaction with the app.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male or female outpatients 18 years of age or older

    • Currently enrolled in an opioid treatment program and receiving medication assisted treatment for opioid use disorder

    • Currently stable in opioid use disorder outpatient treatment for 4 weeks or longer

    • Ability to access the app via smart phone, or tablet.

    Exclusion Criteria:
    • Unwilling or unable to comply with study requirements

    • Have a psychiatric or medical disorder interfering with ability to use the app

    • Incarcerated

    • Pregnant

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Biomedical Development Corporation
    • The University of Texas Health Science Center at San Antonio
    • National Institute on Drug Abuse (NIDA)

    Investigators

    • Principal Investigator: Jennifer Potter, Ph.D., UT Health San Antonio

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Biomedical Development Corporation
    ClinicalTrials.gov Identifier:
    NCT05859035
    Other Study ID Numbers:
    • 23-0232H
    • R42DA054881
    First Posted:
    May 15, 2023
    Last Update Posted:
    May 15, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 15, 2023